Gordon Fykes joins the Acclinate team

Acclinate, a leading digital health company, announced today the appointment of Gordon Fykes as the Head of Business Development. 

‍

Gordon is an award-winning business development and sales executive with over 20 years of experience with Eli Lilly, Novo Nordisk, and Becton Dickinson. He holds a BS in Biology from Tuskegee University. Gordon was the Project Director for a partnership between Eli Lilly and The National Center for Bioethics in Research and Healthcare that resulted in the influential publication entitled "Clinical trials participation among African Americans and the ethics of trust: Leadership perspectives.

‍

Gordon will oversee all business development activities and manage a growing pipeline of pharma clients. He will also handle customer relationships to ensure clients realize their intended ROI from Acclinate's platform and services. 

‍

"Gordon's experience within Fortune 200 pharmaceutical companies and his connectivity to Tuskegee University mean he aligns with our growth objectives while staying true to our mission of health equity through inclusive research. We are excited to have him bring that unique experience to our growing team," said Del Smith, CEO of Acclinate. 

‍

Acclinate is committed to increasing diversity in clinical trials and making it easier for communities of color to participate in clinical trials. By continuously finding mission-aligned superstars such as Gordon, Acclinate continues to innovate and push the clinical trial space to be more equitable and inclusive for communities of color.

‍

"Joining Acclinate at such a critical moment means the world to me. The company continues to grow and reach communities far and wide that I am passionate about. I want to be a part of that," said Gordon.

‍

Acclinate is looking to partner with pharma companies and healthcare organizations that understand and value trust within communities of color. If that is you, we'd love to talk to learn more about your inclusive research needs.